31 July 2014
Company Announcements Office
20 Bridge St
SYDNEY NSW 2000
Invion Limited (ASX:IVX) is pleased to lodge its Appendix 4C for the quarter ending 30 June 2014.
The Company held cash reserves of $3.953 million at the end of June, consistent with budget forecasts. Cash outflows relating to operating expenses ($1.81 million) were marginally higher than the previous quarter ($1.60 million). Net operating cash outflows for the quarter were approximately $1.77 million, further to operating receipts of approximately $0.4 million.
Invion is a life sciences group focussed on the development of treatments for major opportunities in chronic inflammatory respiratory and autoimmune disease. The Group has three drug assets in development, and three phase II clinical trials, regulated by the Food & Drug Administration (FDA), currently underway in the United States.
INV102 (nadolol) is a beta-blocker (beta adrenergic biased ligand) currently marketed as a safe and effective treatment for high blood pressure and chest pain, that has been shown to reverse mucous metaplasia in the airway and is therefore targeted to treat chronic airway diseases including asthma and COPD.
INV104 (zafirlukast) is a leukotriene receptor antagonist (LTRA) and approved oral asthma therapy, that reduces inflammation, constriction of the airways, and the build-up of mucus in the lungs.
INV103 (ala-Cpn10) is a modified, naturally occurring human protein which has been proposed as a founding member of the Resolution Associated Molecular Pattern (RAMPs) family hypothesised to maintain and restore immune homeostasis.
An Appendix 4C accompanies this announcement.
For and on behalf of the Board of Invion Limited